
|Articles|October 8, 2012
FDA gives green light to ANDA for chewable diabetes tablet
FDA has approved Boston Therapeutic’s petition to file an Abbreviated New Drug Application (ANDA) for a new, chewable tablet formulation of the diabetes drug metformin hydrochloride. The company plans to market the new formulation under the name Pazamet.
Advertisement
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Drug Topics
1
Study Identifies Patients at Risk for Severe COVID-19 Post-Vaccination
2
Zepbound Lowers Health Care Costs in Older Adults With Obesity
3
Ixekizumab, Tirzepatide Maintains Efficacy in Psoriatic Disease
4
Measles Resurgence Exposes US Vaccine Policy Risks, Experts Warn
5






































